
The incidence and risk factors of pacemaker (PM) implantation in patients with cardiac amyloidosis (CA) is largely unexplored. Therefore, this study sought to characterise the trends in permanent PM incidence and identify baseline predictors of future PM implantation in the light chain (AL) and transthyretin (ATTR) CA. Consecutive patients with AL and ATTR‐CA diagnosed at participating Centres (2017–2020) were included. Clinical data recorded within ±1 month from diagnosis were collected from electronic medical records. The primary study outcome was the need for clinically‐indicated PM implantation. The absence of these 3 factors had a negative predictive value of 92%, with an area under the curve of 91.8% at 6 months. In a large cohort of AL and ATTR‐CA patients, 8.9% implanted a PM in the 3 years following diagnosis. History of atrial fibrillation, PR >200 ms and QRS >120 ms predicted future PM implantation.
Like
Save
Share